Wellell Biotech Co., Ltd. (stock code 1783) reported its financial results for the fourth quarter of 2025. The company posted an earnings per share (EPS) of NT$2.96 for the quarter. Revenue reached NT$812 million, with a net profit after tax of NT$265 million. Wellell Biotech operates in the biotechnology and medical industry, focusing on collagen and hyaluronic acid.
Company Code: 1783
Company Name: Wellell Biotech Co., Ltd.
Industry: Biotechnology and Medical
Year/Quarter: 2025 Q4
Basic Earnings Per Share: NT$2.96
Operating Revenue: NT$812 million
Net Profit After Tax: NT$265 million
FACT BOX
- Source: PR Times
- Category: 調查